Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014
Ad-Hoc announcement // November 6, 2019, 22:05 CET
Munich – Today Bioeq IP AG, the exclusive owner of the global commercialization rights of Formycon’s biosimilar candidate to Lucentis®1 (FYB201), informed Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) that it has signed a license and development agreement with Coherus BioSciences, Inc. The US Biosimilar-specialist, headquartered in Redwood City, California, will exclusively market and distribute FYB201 in the United States of America (US). Bioeq plans to file the Biologics License Application with the U.S. Food and Drug Administration in the fourth quarter of 2019 and Coherus plans to launch the product in the United States in 2021. Formycon very much appreciates the decision and considers Coherus as a strong and competent partner for a successful commercialization of FYB201 in the US.
1)Lucentis® is a registered trademark of Genentech Inc.